HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Younes, A. Search for Related Content PubMed PubMed Citation Articles by Younes, A. Social Bookmarking                         What's this?

Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma

Correspondence: Anas Younes, MD, Department of Lymphoma/Myeloma, University of Texas-M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 429, Houston, TX 77030; Phone: (713) 792-2860; Fax: (713) 794-5656; e-mail: ayounes{at}mdanderson.org

Abstract

Although classical Hodgkin lymphoma (HL) is considered one of the most curable human cancers, the treatment of patients with relapsed and refractory disease, especially those who relapse after autologous stem cell transplantation, remains challenging. Furthermore, because the median age of the patients is in the mid-30s, the impact of early mortality on the number of years lost from productive life is remarkable. Patients with HL whose disease relapses after stem cell transplantation are rarely cured with current treatment modalities. New drugs and novel treatment strategies that are based on our understanding of the disease biology and signaling pathways are needed to improve treatment outcome for these patients. This review will focus on emerging new treatment modalities that are currently under investigation for patients with relapsed classical HL.

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?